Motus GI Holdings, Inc. · OTC:MOTS
Motus GI — Investor Presentation (December 2023)
22 slides from Motus GI's investor presentation, Dec 5, 2023
Slide 1: Breakthrough Visualization Solutions for GI Procedures
Breakthrough Visualization Solutions for GI Procedures December 2023
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains certain forward-looking statements, including those relating to the Company’s product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, bu
Slide 3: Motus GI
Motus GI IP Protection & First Mover Advantage Our mission is to provide Robust Organization innovative visualization Clinical Structured For Strategic solutions in GI procedures to Results Partnerships improve patient outcomes and experiences. Large Global Experienced Addressable Leadership Markets
Slide 4: Executive Leadership Team
Executive Leadership Team Mark L. Pomeranz I Chief Executive Officer, Board Director Ravit Ram I Chief Financial Officer & VP, Operations Yosi Tzabari I VP, Research and Development Jeff Gnagi I VP, US Sales Elad Amor I Chief Accounting Officer Motus GI | Breakthrough Solutions for GI Procedures 4
Slide 5: Large Global Market Opportunity
Large Global Market Opportunity Focus on Emergent / Inpatient Opportunity >5M 1,2 o Visualization in Emergent Endoscopy, including Upper GI Bleeding is a significant issue that impacts treatment in a patient population with a high Visualization Impaired mortality rate Procedures Annually on a Global
Slide 6: The Unmet Need
The Unmet Need If You Can’t See It, You Can’t Diagnose and Treat It INPATIENT UPPER ENDOSCOPY Pa ti ent Admitted Emergency Upper Procedure Aborted – Bl eed Site Revealed 2 Hr Procedure Upper GI Bleed Endoscopy Bl eed site not revealed And Trea ted INPATIENT COLONOSCOPY Pa ti ent Admitted 24 hr Cl ea
Slide 7: Pure-Vu EVS Solution | Novel Technology Ensures Visualization
Pure-Vu® EVS Solution | Novel Technology Ensures Visualization The Pure-Vu EVS system is indicated to help facilitate the cleaning of a GI tract during an endoscopy procedure. This includes clearing blood, blood clots, and debris in the Upper GI tract as well as fecal matter and debris in the Colon
Slide 8: Our Solution | Novel Technology Ensures Visualization
Our Solution | Novel Technology Ensures Visualization First Mover Advantage with No Competition PULSED VORTEX SMART SENSE SUCTION SMOOTH GLIDE NAVIGATION IRRIGATION 45 Granted Patents Worldwide Motus GI | Breakthrough Solutions for GI Procedures 8
Slide 9: Inpatient Upper GI Bleed: The Unmet Need
Inpatient Upper GI Bleed: The Unmet Need Large clots and bleeding can obscure the field of view and impede treatment Clinical Impact Peptic Ulcers • Procedures can take several hours, and AVM 30% Pain Point many cases only achieve partial hemostasis Esophageal Varices Inadequate • High rebleed rate
Slide 10: Product Design: Pure-Vu EVS Upper GI and Gen 4 Colon
Product Design: Pure-Vu EVS Upper GI and Gen 4 Colon Streamlined, High Margin with Enhanced Capabilities • Streamlined disposable to navigate the GI tract with no sleeve covering the scope that allows the physician to directly hold the scope Large Suction Lumen • Rapid load design for bedside setup
Slide 11: Pure Vu EVS Upper GI Loading Video
Pure Vu EVS Upper GI Loading Video Minimal Training Required Motus GI | Breakthrough Solutions for GI Procedures 11
Slide 12: Clot Suction Video
Clot Suction Video Critical Need in Upper GI Bleeding 2023-12-14 12
Slide 13: High Interest for Pure Vu in Upper GI Bleeding
High Interest for Pure Vu in Upper GI Bleeding Independent 3rd party market research o Showed high interest from GI endoscopists to use Pure Vu in inpatient Upper GI endoscopy with a 9.2 out of 10 rating by hospital based endoscopists o Noted they anticipated using Pure Vu in 30% of all GI bleeding
Slide 14: Pure-Vu Consistently Demonstrates Effective Cleansing in Patients with Poor Bowel Prep
Pure-Vu Consistently Demonstrates Effective Cleansing in Patients with Poor Bowel Prep 4 STUDIES In three multi-centered and one single-center studies, patients presenting with an inadequately prepped colon (as determined by 3 PUBLISHED IN PEER- the Boston Bowel Preparation Scale) became adequately
Slide 15: Establishing a Base of Key Reference Centers
Establishing a Base of Key Reference Centers Creating an Installed Base of Hospital Systems / Supports Future Growth Gaining approvals in large hospital systems Veterans Affair Hospital Focus 215,000 colonoscopies are performed at ~170 VA medical centers/Yr • High rate of inadequate prep • ~ 50% do
Slide 16: Key Company Focus: Building the Foundation for Commercialization Partnerships
Key Company Focus Building the Foundation for Commercialization Partnerships Establishing the Pure Vu Building Market Scaling Towards Growth Drivers Brand Share Profitability • Strong Brand Awareness • Multiple Hospital System • Value Based Pricing • Upper GI Indication • Published Clinical & Agreem
Slide 17: Key Companies in the GI Space
Key Companies in the GI Space Endoscopy Low r GI er e Motus’ Products are Synergistic with Existing and GI p Up Emerging Technologies Sold by Various GI Companies • Hemostasis • AI Polyp Detection • Therapeutic Endoscopy (EMR/ESD) Pure-Vu EVS Creates Unique Differentiation in the Market • Plays in b
Slide 18: A Closer Look at the Pure-Vu EVS Market Growth
A Closer Look at the Pure-Vu EVS Market Growth 2023 2024 2025 and Beyond US US US • INPATIENT • INPATIENT UPPER GI • INPATIENT UPPER GI COLONOSCOPY ENDOSCOPY ENDOSCOPY * • INPATIENT • INPATIENT COLOOSCOPY COLOOSCOPY $5B WW Potential Total Addressable Market OUS REGIONAL EXPANSION OUS REGIONAL EXPANS
Slide 19: Key Upcoming Catalysts
Pure Vu EVS Upper GI and Gen 4 Colon Key Upcoming Market Introduction Catalysts Clinical Data Publications Pure Vu EVS CE Mark / EU-MDR Right product at the right time in the Health System Agreements right markets Commercial Partnerships Motus GI | Breakthrough Solutions for GI Procedures 19
Slide 20: Follow Our Journey. Share in Our Success.
Follow Our Journey. Share in Our Success.
Slide 21: Board of Directors
Board of Directors Timothy P. Moran | Chairman Seasoned commercial and operating executive with experience in both large publicly-traded med-tech and private equity-backed organizations Sonja Nelson | Director Chief Financial Officer of Ambrx BioPharma, Inc with significant management experience wit
Slide 22: References
References Slide Reference 5 1. Estimate for calendar year 2021, based on Motus review and analysis of 2019 inpatient market data and 2021 projections for the U.S., as obtained from iData Research Inc. 2. Estimate based on worldwide colonoscopy market data from 2019 and our review and analysis of 20
Motus GI Holdings — Investor Presentation (December 2023) on 6ix